Global analysis of lysine acetylome reveals the potential role of CCL18 in non‐small cell lung cancer

Kong, Shuai; Ding, Lu; Fan, Chenkun; Li, Yun; Wang, Chi; Wang, Ke; Xu, Weixin; Shi, Xuanming; Wu, Qiulian; Wang, Fengsong

doi:10.1002/pmic.202000144

Cited by 5 publications

(1 citation statement)

References 46 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xanthatin can attenuate PPP in chemoresistance to cisplatin (DDP) resistance for lung cancer, and induce increased ROS levels and apoptosis. This mechanism can mitigate the DDP-resistant antioxidative capacity [ 182 ]. C-C motif chemokine 18 (CCL18), that is M2-tumor-associated macrophages, regulates post-translational modifications in A549 cells via PPP [ 183 ].…”

Section: Blocking Common Nsclc Metabolic Pathways As Anti-nsclcmentioning

confidence: 99%

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine

Bajinka,

Ouedraogo,

Golubnitschaja

et al. 2024

EPMA Journal

View full text Add to dashboard Cite

Energy metabolism is a hub of governing all processes at cellular and organismal levels such as, on one hand, reparable vs. irreparable cell damage, cell fate (proliferation, survival, apoptosis, malignant transformation etc.), and, on the other hand, carcinogenesis, tumor development, progression and metastazing versus anti-cancer protection and cure. The orchestrator is the mitochondria who produce, store and invest energy, conduct intracellular and systemically relevant signals decisive for internal and environmental stress adaptation, and coordinate corresponding processes at cellular and organismal levels. Consequently, the quality of mitochondrial health and homeostasis is a reliable target for health risk assessment at the stage of reversible damage to the health followed by cost-effective personalized protection against health-to-disease transition as well as for targeted protection against the disease progression (secondary care of cancer patients against growing primary tumors and metastatic disease).The energy reprogramming of non-small cell lung cancer (NSCLC) attracts particular attention as clinically relevant and instrumental for the paradigm change from reactive medical services to predictive, preventive and personalized medicine (3PM). This article provides a detailed overview towards mechanisms and biological pathways involving metabolic reprogramming (MR) with respect to inhibiting the synthesis of biomolecules and blocking common NSCLC metabolic pathways as anti-NSCLC therapeutic strategies. For instance, mitophagy recycles macromolecules to yield mitochondrial substrates for energy homeostasis and nucleotide synthesis. Histone modification and DNA methylation can predict the onset of diseases, and plasma C7 analysis is an efficient medical service potentially resulting in an optimized healthcare economy in corresponding areas. The MEMP scoring provides the guidance for immunotherapy, prognostic assessment, and anti-cancer drug development. Metabolite sensing mechanisms of nutrients and their derivatives are potential MR-related therapy in NSCLC. Moreover, miR-495-3p reprogramming of sphingolipid rheostat by targeting Sphk1, 22/FOXM1 axis regulation, and A2 receptor antagonist are highly promising therapy strategies. TFEB as a biomarker in predicting immune checkpoint blockade and redox-related lncRNA prognostic signature (redox-LPS) are considered reliable predictive approaches.Finally, exemplified in this article metabolic phenotyping is instrumental for innovative population screening, health risk assessment, predictive multi-level diagnostics, targeted prevention, and treatment algorithms tailored to personalized patient profiles—all are essential pillars in the paradigm change from reactive medical services to 3PM approach in overall management of lung cancers. This article highlights the 3PM relevant innovation focused on energy metabolism as the hub to advance NSCLC management benefiting vulnerable subpopulations, affected patients, and healthcare at large.

show abstract

Section: Blocking Common Nsclc Metabolic Pathways As Anti-nsclcmentioning

confidence: 99%

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine

Bajinka,

Ouedraogo,

Golubnitschaja

et al. 2024

EPMA Journal

View full text Add to dashboard Cite

show abstract

GSE1 promotes the proliferation and migration of lung adenocarcinoma cells by downregulating KLF6 expression

Meng,

Yang,

et al. 2024

Cell Biology International

View full text Add to dashboard Cite

Lung cancer is one of the most prevalent human cancers with a high lethality rate worldwide. In this study, we demonstrated that GSE1 (genetic suppressor element 1) expression is aberrantly upregulated in lung adenocarcinoma and that GSE1 depletion inhibits the proliferation and migration of both A549 and H1299 cells. Immunoprecipitation assays demonstrated that GSE1 interacts with histone deacetylase 1 (HDAC1) and other BRAF–HDAC complex (BHC) components in cells. The transcriptome of GSE1‐knockdown A549 cells indicated that 207 genes were upregulated and 159 were downregulated based on a p‐value < .05 and fold change ≥ 1.5. Bioinformatics analysis suggested that 140 differentially expressed genes harbor binding sites for HDAC1, including the tumor suppressor gene KLF6 (Kruppel‐like factor 6). Indeed, quantitative reverse‐transcription polymerase chain reaction and western blot analysis revealed that GSE1 could inhibit the transcription of KLF6 in lung cancer cells. In conclusion, GSE1 cooperates with HDAC1 to promote the proliferation and metastasis of non‐small cell lung cancer cells through the downregulation of KLF6 expression.

show abstract

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

Ren,

Liu

et al. 2024

Computational Biology and Chemistry

View full text Add to dashboard Cite

Global analysis of lysine acetylome reveals the potential role of CCL18 in non‐small cell lung cancer

Cited by 5 publications

References 46 publications

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine

GSE1 promotes the proliferation and migration of lung adenocarcinoma cells by downregulating KLF6 expression

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

Contact Info

Product

Resources

About